By Martin Shwenk Leade
AstraZeneca’s baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant hypertension, boosting the company’s shares. The drug, acquired through CinCor Pharma, targets aldosterone and is projected to generate over $5 billion in peak annual sales. AstraZeneca is exploring baxdrostat across multiple indications, with full trial results expected in August.